Kymera Therapeutics

Kymera Therapeutics is a clinical-stage biopharmaceutical company headquartered at 500 North Beacon Street in Watertown, Massachusetts, pioneering targeted protein degradation as a way to build oral small-molecule medicines against targets that conventional inhibitors cannot reach. Rather than blocking a protein's activity, Kymera's degraders recruit the body's own protein-disposal machinery so that a binding event alone is sufficient to eliminate the disease-driving protein, an approach the company describes as a disease-agnostic modality. Its wholly-owned pipeline is led by KT-621, a once-daily oral STAT6 degrader in Phase 2 for Type 2 inflammatory diseases including atopic dermatitis, asthma, COPD and chronic spontaneous urticaria, and KT-579, a first-in-class oral IRF5 degrader in Phase 1 for lupus, Sjogren's syndrome and rheumatoid arthritis. Partnered programs include the oral IRAK4 degrader KT-485/SAR447971 with Sanofi and the CDK2 molecular glue degrader KT-200 with Gilead Sciences. Kymera publishes no public developer API or developer portal; this profile captures the company's public web, investor, patient and security surface for the API Evangelist network.

Kymera Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotech, Pharmaceuticals, Life Sciences, and Drug Discovery.

Kymera Therapeutics’ developer surface includes support and 17 more developer resources.

🌐 Visit website 📡 Source on GitHub

15.2/100 emerging ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechPharmaceuticalsLife SciencesDrug DiscoveryTargeted Protein DegradationImmunologyOncologyClinical TrialsHealthcare

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 15.2/100 · emerging

Contract Quality 0.0 / 25

Developer Ergonomics 0.9 / 20

Commercial Clarity 4.2 / 20

Operational Transparency 0.7 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/kymera-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Build 2

SDKs, sample code, and the tooling you integrate with

GitHubOrganization

GitHubOrganization

ResourceLibrary

ResourceLibrary

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 2

Status, limits, changes, and where to get help

Contact

Contact

Support

Support

Commercial 2

Pricing, plans, and the legal terms of use

TermsOfService

TermsOfService

PrivacyPolicy

PrivacyPolicy

Company 7

The organization behind the API

Website

About

Careers

Investors

Press

LinkedIn

Twitter

Twitter

Scroll for all 7

Other 3

Properties that don't map to a standard resource type

Pipeline

Pipeline

Science

Science

Patients

Patients

Source (apis.yml)

aid: kymera-therapeutics
name: Kymera Therapeutics
description: Kymera Therapeutics is a clinical-stage biopharmaceutical company headquartered at 500 North Beacon Street in
  Watertown, Massachusetts, pioneering targeted protein degradation as a way to build oral small-molecule medicines against
  targets that conventional inhibitors cannot reach. Rather than blocking a protein's activity, Kymera's degraders recruit
  the body's own protein-disposal machinery so that a binding event alone is sufficient to eliminate the disease-driving protein,
  an approach the company describes as a disease-agnostic modality. Its wholly-owned pipeline is led by KT-621, a once-daily
  oral STAT6 degrader in Phase 2 for Type 2 inflammatory diseases including atopic dermatitis, asthma, COPD and chronic spontaneous
  urticaria, and KT-579, a first-in-class oral IRF5 degrader in Phase 1 for lupus, Sjogren's syndrome and rheumatoid arthritis.
  Partnered programs include the oral IRAK4 degrader KT-485/SAR447971 with Sanofi and the CDK2 molecular glue degrader KT-200
  with Gilead Sciences. Kymera publishes no public developer API or developer portal; this profile captures the company's
  public web, investor, patient and security surface for the API Evangelist network.
url: https://raw.githubusercontent.com/api-evangelist/kymera-therapeutics/refs/heads/main/apis.yml
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://www.kymeratx.com/wp-content/uploads/2023/12/Kymera_OG_Image-A.png
x-type: company
x-source: vc-portfolio
x-backed-by:
- bessemer-venture-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotech
- Pharmaceuticals
- Life Sciences
- Drug Discovery
- Targeted Protein Degradation
- Immunology
- Oncology
- Clinical Trials
- Healthcare
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.kymeratx.com
- type: About
  url: https://www.kymeratx.com/about-us/
- type: Contact
  url: https://www.kymeratx.com/contact-us/
- type: Support
  url: https://www.kymeratx.com/contact-us/
- type: TermsOfService
  url: https://www.kymeratx.com/terms-of-use/
- type: PrivacyPolicy
  url: https://www.kymeratx.com/privacy-policy/
- type: GitHubOrganization
  url: https://github.com/kymeratx
- type: Careers
  url: https://www.kymeratx.com/careers-culture/
- type: Investors
  url: https://investors.kymeratx.com/
- type: Press
  url: https://www.kymeratx.com/media/
- type: Pipeline
  url: https://www.kymeratx.com/science-innovation/pipeline/
- type: Science
  url: https://www.kymeratx.com/science-innovation/our-approach/
- type: Patients
  url: https://patients.kymeratx.com/
- type: ResourceLibrary
  url: https://www.kymeratx.com/resource-library/
- type: LinkedIn
  url: https://www.linkedin.com/company/kymeratherapeutics/
- type: Twitter
  url: https://twitter.com/KymeraTx
- type: DomainSecurity
  url: security/kymera-therapeutics-domain-security.yml
- type: LLMsTxt
  url: llms/kymera-therapeutics-llms.txt
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence